What is Evozyne?
Evozyne operates at the critical intersection of computational biology and therapeutic development. By leveraging its proprietary EvoGen platform, the company designs novel therapeutic proteins optimized for potency, stability, and specificity. Unlike traditional drug discovery methods, Evozyne utilizes a high-throughput facility known as EvoLab to synthesize and validate thousands of protein candidates, creating a robust data loop that informs its immunology pipeline. This approach allows the firm to target patient populations that have historically been underserved by conventional pharmaceutical interventions, positioning Evozyne as a transformative force in the biotechnology sector.
How much funding has Evozyne raised?
Evozyne has raised a total of $81M across 1 funding round:
Series B
$81M
Series B (2023): $81M with participation from Valor Equity Partners, NVIDIA, Fidelity, Paragon Biosciences, and OrbiMed
Key Investors in Evozyne
NVIDIA
A global technology leader specializing in GPU design and AI computing solutions, providing the high-performance infrastructure necessary for complex biological modeling.
OrbiMed
A specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals and life sciences with deep expertise in innovation cycles.
Fidelity
A diversified financial services firm providing institutional-grade investment and wealth management solutions to support long-term growth and innovation.
What's next for Evozyne?
With this recent infusion of capital, Evozyne is well-positioned to scale its operations and deepen its research capabilities. The strategic focus will likely center on expanding the EvoGen platform's predictive accuracy and accelerating the transition of lead candidates into clinical development. As the company continues to refine its generative models, it aims to solidify its market position by delivering scalable, high-efficacy therapies. The involvement of high-profile technology and life science investors suggests a long-term roadmap focused on establishing a dominant footprint in the next generation of AI-driven medicine.
See full Evozyne company page
